Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy

About 70–80% of early breast cancer (BC) patients receive adjuvant endocrine therapy (ET) for at least 5 years. ET includes in the majority of cases the use of aromatase inhibitors, as upfront or switch strategy, that lead to impaired bone health. Given the high incidence and also the high prevalenc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Curr Treat Options Oncol
Autori principali: Diana, Anna, Carlino, Francesca, Giunta, Emilio Francesco, Franzese, Elisena, Guerrera, Luigi Pio, Di Lauro, Vincenzo, Ciardiello, Fortunato, Daniele, Bruno, Orditura, Michele
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2021
Soggetti:
Breast Cancer (WJ Gradishar, Section Editor)
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8052225/
https://ncbi.nlm.nih.gov/pubmed/33864145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-021-00835-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi